Dopamine D3 Receptor Antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 484-492

  Appel, Nathan M ^a   Li, Shou Hua ^a   Holmes, Tyson H ^b   Acri, Jane B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; GSK 598809; AZABICYCLO DERIVATIVE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BEAGLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONSCIOUSNESS; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; HEART FUNCTION; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; TELEMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; BEHAVIOR, ADDICTIVE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COCAINE-RELATED DISORDERS; DOG; DRUG EFFECTS;

ANIMALS; AZABICYCLO COMPOUNDS; BEHAVIOR, ADDICTIVE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COCAINE; COCAINE-RELATED DISORDERS; DOGS; DOPAMINE ANTAGONISTS; MALE; OXAZOLES; RECEPTORS, DOPAMINE D3;

EID: 84941595640     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.224121     Document Type: Article

References (53)

1. Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, and Spealman RD (2010) Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 334:556-565.
2. Amenta F, Ricci A, Tayebati SK, and Zaccheo D (2002) The peripheral dopaminergic system: morphological analysis, functional and clinical applications. Ital J Anat Embryol 107:145-167.
3. Armando I, Villar VA, Jones JE, Lee H, Wang X, Asico LD, Yu P, Yang J, Escano CS Jr, and Pascua-Crusan AM, et al. (2014) Dopamine D3 receptor inhibits the ubiquitin-specific peptidase 48 to promote NHE3 degradation. FASEB J 28: 1422-1434.
4. Armando I, Villar VA, and Jose PA (2011) Dopamine and renal function and blood pressure regulation. Compr Physiol 1:1075-1117.
5. Ashby CR Jr, Paul M, Gardner EL, Heidbreder CA, and Hagan JJ (2003) Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 48:154-156.
6. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, and Jose PA (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 102:493-498.
7. Cervo L, Cocco A, Petrella C, and Heidbreder CA (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 10:167-181.
8. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
9. Ewart L, Milne A, Adkins D, Benjamin A, Bialecki R, Chen Y, Ericsson AC, Gardner S, Grant C, and Lengel D, et al. (2013) A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. J Pharmacol Toxicol Methods 68:30-43.
10. Galaj E, Ananthan S, Saliba M, and Ranaldi R (2014) The effects of the novel DA D3 receptor antagonist SR 21502 on cocaine reward, cocaine seeking and cocaine-induced locomotor activity in rats. Psychopharmacology (Berl) 231: 501-510.
11. Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng XQ, and Xi ZX (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57:17-28.
12. Goldstein RA, DesLauriers C, Burda A, and Johnson-Arbor K (2009) Cocaine: history, social implications, and toxicity: A review. Semin Diagn Pathol 26:10-17.
13. Hachimine P, Seepersad N, Ananthan S, and Ranaldi R (2014) The novel dopamine D3 receptor antagonist, SR 21502, reduces cocaine conditioned place preference in rats. Neurosci Lett 569:137-141.
14. Heidbreder C (2013) Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn Schmiedebergs Arch Pharmacol 386:167-176.
15. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, and Ashby CR Jr (2005) The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Brain Res Rev 49:77-105.
16. Heidbreder CA and Newman AH (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 1187:4-34.
17. Johnson TL, Tulis DA, Keeler BE, Virag JA, Lust RM, and Clemens S (2013) The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis. PLoS One 8:e74116.
18. Le Foll B, Goldberg SR, and Sokoloff P (2005) The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-541.
19. Le Foll B, Goldberg SR, and Sokoloff P (2007) Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 16:45-57.
20. Le Foll B, Schwartz JC, and Sokoloff P (2000) Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 15:140-146.
21. Levant B, Grigoriadis DE, and DeSouza EB (1993) [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J Pharmacol Exp Ther 264:991-1001.
22. Lewington S, Clarke R, Qizilbash N, Peto R, and Collins R; Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913.
23. Luippold G, Küster E, Joos TO, and Mühlbauer B (1998) Dopamine D3 receptor activation modulates renal function in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 358:690-693.
24. Luippold G, Pech B, Schneider S, Drescher K, Müller R, Gross G, and Mühlbauer B (2006) Absence of amino acid-induced glomerular hyperfiltration in dopamine D3 receptor knockout mice. Naunyn Schmiedebergs Arch Pharmacol 372:284-290.
25. Mash DC (1997) D3 receptor binding in human brain during cocaine overdose. Mol Psychiatry 2:5-6.
26. Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, and Fontana S, et al. (2010) 1, 2, 4-Triazolyl azabicyclo [3.1.0]hexanes: A new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 53:374-391.
27. Micheli F and Heidbreder C (2006) Selective dopamine D3 receptor antagonists: A review 2001-2005. Recent Patents CNS Drug Discov 1:271-288.
28. Milliken GA and Johnson DE (1992) Analysis of Messy Data, Vol 1: Designed Experiments, Chapman & Hall/CRC, Boca Raton, FL.
29. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, Rabiner EA, Micheli F, and Heidbreder C, et al. (2013) Occupancy of brain dopamine D3 receptors and drug craving: A translational approach. Neuropsychopharmacology 38:302-312.
30. Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, and McCluskey T, et al. (2014) Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: A positron emission tomography study with [11C]-1-PHNO. Neuropsychopharmacology 39: 311-318.
31. Peng XQ, Ashby CR Jr, Spiller K, Li X, Li J, Thomasson N, Millan MJ, Mocaër E, Muńoz C, and Gardner EL, et al. (2009) The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drugseeking behavior in rats. Neuropharmacology 56:752-760.
32. Pugsley MK, Authier S, and Curtis MJ (2008) Principles of safety pharmacology. Br J Pharmacol 154:1382-1399.
33. Rice OV, Gardner EL, Heidbreder CA, and Ashby CR Jr (2012) The acute administration of the selective dopamine D(3) receptor antagonist SB-277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats. Synapse 66:85-87.
34. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, and Merlo-Pich E, et al. (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399.
35. Sokal RR and Rohlf FJ (1981) Biometry: The Principles and Practice of Statistics in Biological Research, W. H. Freeman, San Francisco.
36. Sokoloff P, Giros B, Martres MP, Bouthenet ML, and Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
37. Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaál J, Xi ZX, and Gardner EL (2012) YQA14: A novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 17:259-273.
38. Song R, Bi GH, Zhang HY, Yang RF, Gardner EL, Li J, and Xi ZX (2014) Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drugseeking behavior in rats. Neuropharmacology 77:398-405.
39. Sordo L, Indave BI, Barrio G, Degenhardt L, de la Fuente L, and Bravo MJ (2014) Cocaine use and risk of stroke: A systematic review. Drug Alcohol Depend 142: 1-13.
40. Staley JK and Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
41. Swanson LW (1982) The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9:321-353.
42. te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, and van Gerven JM (2012) Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. J Psychopharmacol 26:303-314.
43. U.S. Food and Drug Administration (FDA) (2001) Guidance for Industry S7A Safety Pharmacology Studies for Human Pharmaceuticals, FDA, Silver Spring, MD.
44. Van de Water A, Verheyen J, Xhonneux R, and Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22:207-217.
45. Vorel SR, Ashby CR Jr, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, and Gardner EL (2002) Dopamine D3 receptor antagonism inhibits cocaineseeking and cocaine-enhanced brain reward in rats. J Neurosci 22:9595-9603.
46. Walsh JJ and Han MH (2014) The heterogeneity of ventral tegmental area neurons: Projection functions in a mood-related context. Neuroscience 282C:101-108.
47. Wise RA and Bozarth MA (1985) Brain mechanisms of drug reward and euphoria. Psychiatr Med 3:445-460.
48. Xi ZX and Gardner EL (2007) Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 13:240-259.
49. Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, and Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21:3427-3438.
50. Yu C, Yang Z, Ren H, Zhang Y, Han Y, He D, Lu Q, Wang X, Wang X, and Yang C, et al. (2009) D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. Am J Hypertens 22:877-883.
51. Zeng C, Asico LD, Yu C, Villar VA, Shi W, Luo Y, Wang Z, He D, Liu Y, and Huang L, et al. (2008) Renal D3 dopamine receptor stimulation induces natriuresis by endothelin B receptor interactions. Kidney Int 74:750-759.
52. Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, and Jose PA (2004) Functional genomics of the dopaminergic system in hypertension. Physiol Genomics 19: 233-246.
53. Zimmerman JL (2012) Cocaine intoxication. Crit Care Clin 28:517-526.